Medicare GLP-1 Coverage for Weight Loss: The $50 Bridge

For years, Medicare GLP-1 coverage for weight loss was a flat no: Part D was barred from paying for drugs used for weight loss alone. That changed on July 1, 2026. The Medicare GLP-1 Bridge, a temporary CMS demonstration, now lets eligible Part D beneficiaries get Wegovy, Zepbound, or Foundayo for a flat $50 monthly copay through December 31, 2027 (CMS press release, May 2026).

The headlines have covered the announcement. What most of them skip is the operational part: whether you specifically qualify, what your doctor has to submit and to whom, what the $50 does and doesn't buy you, and what your options are if you're turned down. That's this guide. These medications require a prescription, so every step here runs through a licensed healthcare provider.

Last verified: 2026-07-28 by RxPickr Editorial Team. Program rules below were verified against CMS program pages and KFF analysis on the date shown. Provider pricing reflects our most recent checkout verification and may change; our live pricing tool always shows current figures. See our methodology.

What the Medicare GLP-1 Bridge Actually Is

The Bridge is not a change to your Part D plan's formulary. It's a Section 402 demonstration that operates entirely outside the Part D benefit's coverage and payment flow. Your drug plan doesn't opt in, doesn't carry the cost, and doesn't process the claim. In 2026, CMS uses a single central processor to handle prior authorization, claims adjudication, and payment to pharmacies (CMS, Medicare GLP-1 Bridge).

Two dates matter. The program started July 1, 2026 and runs through December 31, 2027. CMS already extended it once: the original end date was December 31, 2026, and the extension came after the related BALANCE payment model failed to launch in Part D for 2027 (KFF).

Scale-wise, this is significant. A KFF analysis of 2023 claims data estimated that 3.8 million Medicare beneficiaries met the eligibility criteria (KFF, June 2026).

Are You Eligible?

You need to clear three separate gates: the right plan type, the right clinical profile, and the right reason for the prescription.

Gate 1: Your plan type

You must be enrolled in CY 2026 in either a standalone Part D prescription drug plan (PDP) or a Medicare Advantage coordinated care plan with drug coverage (an MA-PD that is an HMO, HMO-POS, or local or regional PPO). Special Needs Plans, employer/union group waiver plans, and the LI NET program also qualify. Beneficiaries in private fee-for-service plans, cost plans, PACE, and a few other plan types are excluded unless they also hold a standalone PDP (CMS provider FAQ). Dual-eligible beneficiaries in qualifying plan types can participate.

Gate 2: The clinical criteria

Your prescriber must attest that you are at least 18, that the drug is prescribed to reduce excess body weight and maintain weight reduction alongside ongoing lifestyle modification, and that you meet one of three BMI tiers (CMS provider FAQ):

• BMI 35 or higher: qualifies on its own.
• BMI 30 or higher plus at least one of: heart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 despite two antihypertensive medications), or chronic kidney disease stage 3a or above.
• BMI 27 or higher plus at least one of: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Here's the detail that trips people up: the criteria apply at the time you started GLP-1 therapy, not today. CMS's own example: someone who started in September 2024 at a BMI of 37 and is now at 34 still qualifies, because they met the BMI 35 threshold at initiation. If you've already lost weight on a GLP-1 you were paying cash for, that earlier starting point is what your doctor attests to.

Gate 3: The reason for the prescription

The Bridge covers weight management only. If you have type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH (a form of fatty liver disease), those indications are already coverable under regular Part D, and CMS says you're ineligible for the Bridge even if you meet the BMI criteria. Same logic if the drug is being prescribed to reduce cardiovascular event risk: that prescription routes to your Part D plan, not the Bridge (CMS provider FAQ).

Which Drugs and Formulations Are Covered

The covered list is specific down to the pen type (CMS provider FAQ):

Drug	Active ingredient	What the Bridge covers
Wegovy	semaglutide	All formulations (injection pens and tablets)
Foundayo	orforglipron	All formulations (oral pill)
Zepbound	tirzepatide	KwikPen only. Single-dose vials and single-dose pens are excluded.

Two practical notes. If you currently use Zepbound vials (common among cash-pay patients), you'd need to switch to the KwikPen to use the Bridge; talk to your prescriber about that transition. And pen needles for the Zepbound KwikPen are not covered, so budget a few dollars for those separately.

Step by Step: How to Actually Get It

There is no application and no separate enrollment. The process runs through your prescriber and pharmacy.

1. Talk to your doctor. Confirm you meet a BMI tier (as of therapy initiation) and that the prescription is for chronic weight management. Any licensed prescriber who is not on Medicare's Preclusion List can participate; they do not need to be enrolled in Medicare.
2. Your doctor sends the prescription to your pharmacy for one of the covered drugs. CMS recommends (but does not require) including the diagnosis code and a note directing the pharmacy to route the claim to the Medicare GLP-1 Bridge.
3. The pharmacy transmits the claim to the Bridge's central processor, not your Part D plan. No Part D denial is required first.
4. The processor sends a prior authorization request to your doctor, electronically or by fax, typically within 24–72 hours. Your doctor completes it, attesting to the clinical criteria above. If nothing arrives after 72 hours, your doctor can download the fax form from CMS and submit it directly.
5. You get a decision within 72 hours of the prior authorization submission. The approval or denial is mailed to you and sent to your prescriber.
6. Pick up your medication and pay $50 at the pharmacy counter for a monthly supply.

All process details per the CMS provider FAQ. Questions along the way: beneficiaries can call 1-800-MEDICARE, and prescribers can call the Bridge call center at 855-273-0102 (weekdays 8am–7pm ET). CMS also maintains a beneficiary page at Medicare.gov/glp1bridge.

What the $50 Buys, and What It Doesn't

The copay is genuinely flat: $50 per monthly supply, at every dose, in every month of the year. But because the Bridge sits outside Part D, the fine print cuts the other way too (CMS):

For context on the economics: KFF reports the manufacturers' net price to the program is $245 per monthly supply, with Medicare paying the difference above your $50, and none of it counting toward the regular Part D out-of-pocket cap of $2,100 in 2026 (KFF). Fifty dollars a month is a fraction of typical cash-pay pricing for these drugs, which you can compare on our live pricing tool.

If Your Prior Authorization Is Denied

The Bridge has no appeals process. That's not a typo: CMS states there is no appeal mechanism under the demonstration. What your prescriber can do is resubmit the prior authorization form with corrected or additional information, which is the right move if the denial stemmed from a data-entry error, a missing diagnosis, or an initiation-date BMI that wasn't documented clearly the first time (CMS provider FAQ).

If you were denied because your indication belongs in regular Part D (diabetes, sleep apnea, MASH, cardiovascular risk reduction), that's actually a redirect, not a dead end: your Part D plan's normal coverage and appeals machinery applies. Our denial appeal guide focuses on commercial insurance, but the documentation principles carry over.

If You Don't Qualify at All

Plenty of people won't clear the gates: BMI between 27 and 30 with no qualifying condition, an ineligible plan type, or a BMI under 27 entirely. You still have paths, all cash-pay.

Manufacturer-direct programs are the most direct brand-name route. LillyDirect sells Zepbound and Foundayo directly from Eli Lilly, and NovoCare Pharmacy sells Wegovy directly from Novo Nordisk, so you're buying through the manufacturer's own pharmacy channel at its published self-pay price, though you'll need a prescription in hand.

Compounded GLP-1s are the budget route. Providers like TrimRx, Oak Longevity, Enhance.MD, and Shed offer compounded semaglutide or tirzepatide at a fraction of brand pricing. Compounded versions contain the same active ingredient but are not FDA-approved as finished products, and the Bridge does not cover them under any circumstances. Our guide to getting GLP-1s without insurance breaks down the full cash-pay decision.

And if your regular doctor is unwilling to manage GLP-1 therapy at all, telehealth clinicians can prescribe these medications too. CMS confirms a prescriber doesn't need Medicare enrollment to write a Bridge prescription or submit the prior authorization, only a clean status off the Preclusion List.

Not sure which route fits your budget and situation? Our quiz sorts it out fast.

What Happens After December 2027

Honest answer: nobody knows yet. The Bridge was built as a stopgap while CMS develops the BALANCE model, a longer-term approach to paying for GLP-1s in Medicare and Medicaid. BALANCE didn't launch in Part D for 2027 (KFF attributes this to insufficient plan participation), which is why the Bridge got its extension. KFF's assessment is blunt: it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 for obesity after the Bridge ends (KFF).

Two practical takeaways. First, don't build a long-term budget around the $50 lasting forever; know what the cash-pay fallback costs before you start. Second, if you qualify now, starting under the Bridge creates a documented record of your eligibility and therapy initiation, which may matter if a successor program inherits similar criteria.

If you think you qualify, the next step is a conversation with your doctor, ideally with your BMI history and any qualifying diagnoses pulled up. If you don't, take the quiz and see what the cash-pay market looks like for your situation.